RxDoctor Payments Data

Jennifer Toro Galarza, MD

Internal Medicine · Lady Lake, FLNPI 1720411598

Payments from drug & device makers

$2,385in general payments, 2019–2025

Across 143 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$612
  • AbbVie$415
  • Lilly USA, LLC$266
  • Esperion Therapeutics, Inc.$250
  • GSK$217
  • Pfizer$86
  • plus $538 from 13 others

What the payments were for

  • Food & beverage$2,385100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,385 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$193,565
Medicare patients
736
Services billed
2,656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide115$173,378
EliquisApixaban88$111,161
MounjaroTirzepatide66$97,907
JardianceEmpagliflozin55$87,268
RybelsusSemaglutide39$61,495
TrulicityDulaglutide31$50,895
ProliaDenosumab27$47,161
FarxigaDapagliflozin Propanediol29$42,455
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$38,128
JanuviaSitagliptin Phosphate23$35,849
EntrestoSacubitril/Valsartan19$25,735
Tresiba Flextouch U-200Insulin Degludec11$22,003
XareltoRivaroxaban16$20,001
Tresiba Flextouch U-100Insulin Degludec29$15,311
TradjentaLinagliptin13$9,564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$612$234,873154 claims
Lilly USA, LLCMounjaro, Trulicity$266$148,80297 claims
PfizerEliquis$86$111,16188 claims
AmgenProlia$15$47,16127 claims
AstraZenecaFarxiga$62$42,45529 claims
GSKTrelegy Ellipta$217$38,12844 claims
NovartisEntresto$34$25,73519 claims
Johnson & JohnsonXarelto$72$20,00116 claims
AbbVieSynthroid$415$8,69097 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Lady Lake

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →